The research, unveiled in Las Vegas this September, underscores a decade of clinical development for the fixed-dose combination of 650 mg of acetaminophen and 220 mg of naproxen sodium. In trials involving dental surgery and bunionectomy patients, the medication demonstrated superior efficacy compared to its individual components. Specifically, the bunionectomy study revealed that patients using the combination reduced their reliance on opioid rescue medication by nearly 40% over 48 hours.
Tylenol with Naproxen Data Highlights Non-Opioid Pain Relief Efficacy
Clinical data presented at the 20th annual PAINWeek conference confirms that the newly FDA-approved Tylenol with Naproxen provides sustained pain relief in post-surgical settings. The findings, derived from two pivotal Phase 3 trials, position the over-the-counter combination as a potent, non-opioid alternative for managing acute discomfort.
Dr. Rajesh Mishra, Chief Medical Officer at Kenvue, noted that the product addresses a critical gap for patients who currently face a choice between short-term relief and more complex, often invasive management strategies. By pairing the rapid onset of acetaminophen with the 12-hour duration of naproxen, the medication offers a streamlined approach for clinical recommendations. The data presented at PAINWeek, which includes four scientific posters, builds upon earlier proof-of-concept studies suggesting this combination outperforms certain hydrocodone-based treatments. The product is expected to reach major U.S. retailers nationwide shortly.
Comments (0)
No comments yet. Be the first!